Naltrexone, Acamprosate, or Disulfiram? How Families Can Help Choose an Alcohol Medication
A practical family guide to the three FDA-approved alcohol medications: what naltrexone, acamprosate and disulfiram each do, who they fit, and what to ask.

Most families who call a treatment center about a drinking problem have already heard the words detox, counseling, and AA. Far fewer have heard that the Food and Drug Administration has approved three medications for alcohol use disorder, that all three are nonaddictive, and that one of them might change what the next year looks like.
That gap is worth closing before the next appointment. NIAAA estimates that millions of American adults have alcohol use disorder and that roughly one in ten children lives in a home with a parent who has it — so this is not a rare decision, even though it is rarely explained in plain language.
This guide is not a prescription and it does not pick a drug for anyone. It is a map of the decision: what each medication does, who it tends to fit, who should not take it, what the research actually shows, and the questions worth putting to a prescriber.
What These Medications Actually Do
None of the three works like a substitute drug. NIAAA describes them as treatment for a chronic condition, in the same sense that someone takes medication for asthma or diabetes, and notes that all approved alcohol medications are nonaddictive.
They also do different jobs. Naltrexone changes the reward side of drinking — it blocks opioid receptors involved in the pleasurable effects of alcohol and in craving. Acamprosate is thought to work on the withdrawal side, reducing the protracted unease that follows heavy drinking by counteracting the imbalance between the glutamatergic and GABAergic systems. Disulfiram is neither: it makes drinking physically unpleasant, so the deterrent is knowledge rather than pharmacology alone.
That difference matters when you are choosing. A person tormented by craving at 6 p.m. has a different problem from a person who feels flat, restless and sleepless three weeks into abstinence, and a different problem again from someone who needs a hard external brake. Matching the medication to the problem is the whole art of the decision.
The Three Medications in Detail
The table below is a summary from SAMHSA's clinical guide and the product labeling. Doses are listed so that you can recognize what is being proposed and ask about it — not so that you can adjust anything yourself.
| Medication | How it is taken | Main effect | Typical candidate |
|---|---|---|---|
| Naltrexone, oral | One 50 mg tablet daily | Reduces craving and the reward from drinking | Someone who has already stopped for several days and wants to drink less or not at all |
| Naltrexone, extended-release | 380 mg deep gluteal injection every 4 weeks | Same, with no daily pill to remember | Someone who struggles with daily adherence, or who wants a monthly commitment |
| Acamprosate | Two 333 mg tablets three times a day | Supports abstinence by easing protracted withdrawal | Someone who is already abstinent and wants help staying there |
| Disulfiram | 250 mg daily (range 125–500 mg, never above 500 mg) | Makes any drinking produce a physical reaction | A supervised, committed person who wants an enforced brake |
Naltrexone
Oral naltrexone is the most studied of the three in American settings. The label recommends 50 mg once daily for most patients, and SAMHSA's guidance notes that both formulations appear to work best in people who can stop drinking on their own for several days before starting — naltrexone has not been shown to be effective in patients who are drinking at treatment initiation.
The monthly injection removes the daily decision. It must be given by a health care provider as a deep intramuscular gluteal injection, every four weeks, and it is not recommended at intervals shorter than that or at doses above 380 mg. Because it is a depot, it cannot be withdrawn quickly if a problem develops, which is a real trade-off rather than a marketing detail.
Acamprosate
Acamprosate is taken as two 333 mg tablets three times a day, which is 666 mg per dose and just under 2,000 mg a day — a schedule most people underestimate until they are holding the bottle. The label reduces the dose to one tablet three times a day for moderate renal impairment (creatinine clearance 30–50 mL/min) and contraindicates it entirely below that, so kidney function is checked first.
It is usually started about five days after drinking stops and reaches full effect in five to eight days. Unusually among these drugs, treatment is meant to continue even if the person drinks again. The feasibility problem is arithmetic: three times a day, every day, is a schedule that fits badly with shift work, homelessness, or a chaotic household.
Disulfiram
Disulfiram works only if the person takes it knowingly and does not drink. The label is unusually blunt about this: it should never be given in a state of intoxication or without the patient's full knowledge, and relatives are to be instructed accordingly.
It cannot be started until the person has been abstinent for at least 12 hours. Initial treatment is up to 500 mg daily for one to two weeks, then a maintenance dose averaging 250 mg, with 500 mg as the ceiling. The reaction it produces — flushing, throbbing headache, nausea and vomiting, sweating, chest pain, palpitations, breathlessness, low blood pressure, and in severe cases respiratory depression, arrhythmia, heart attack, convulsions or death — can occur for up to 14 days after the last dose, and small amounts count. The label warns specifically about alcohol hidden in sauces, vinegars, cough mixtures, aftershave lotions and back rubs.
This is why disulfiram is the medication that most depends on a household. It is also the one most likely to be prescribed badly: handed to someone living alone with no supervision and no follow-up, where it becomes a daily test of willpower rather than a support.
The Rule That Decides Most Cases
Before comparing drugs, families should understand the sequencing rule that eliminates many options in advance: these medications are largely started after drinking has stopped, not instead of stopping.
Acamprosate is indicated for maintaining abstinence in people who are already abstinent, and its efficacy has not been demonstrated in people who have not completed withdrawal. Naltrexone has not been shown to be effective in people still drinking at initiation. Disulfiram requires at least 12 hours of abstinence just to start safely.
That is not a technicality. It means the first conversation is about safe withdrawal, not about which pill. Alcohol withdrawal can be severe and occasionally fatal, it generally begins within 24 to 48 hours after the blood alcohol level falls and can persist for five to seven days, and a history of three or four previous withdrawal episodes raises the likelihood of severe symptoms without adequate medical care. If your family member has been drinking heavily and daily, the medication question comes after a medically managed detox — see our guide to detox and withdrawal management for what that involves.
It also means that a treatment program which offers medication but has no plan for the first week is offering half an answer.
The Opioid Problem Nobody Warns Families About
Naltrexone is an opioid blocker. That single fact creates interactions that catch families off guard, and they are worth understanding before anyone signs a consent form.
Naltrexone is contraindicated in people receiving opioid analgesics, in people with current opioid dependence including maintenance on methadone or buprenorphine, in acute opioid withdrawal, and in anyone with a positive opioid urine screen. Patients must be opioid-free for a minimum of 7 to 10 days before starting; for people switching from buprenorphine or methadone, the label warns of vulnerability to precipitated withdrawal for as long as two weeks, which can be severe enough to require hospitalization.
Two practical consequences follow. First, a person who takes opioids for chronic pain, or who is scheduled for surgery or dental surgery, needs the prescriber to know about the naltrexone before any opioid is given — SAMHSA's guidance tells patients to inform all physicians and dentists for exactly this reason.
Second, and more dangerous: after naltrexone treatment, tolerance is reduced. The injectable label warns that patients are vulnerable to a potentially fatal overdose at the end of a dosing interval, after a missed dose, or after stopping — and that trying to overcome the blockade can also be fatal. SAMHSA recommends that people at risk of opioid overdose be offered naloxone when naltrexone is discontinued. If there is any opioid use in the household's story, this is not a theoretical risk.
What the Evidence Actually Shows
Families are often told these drugs "work." Here is what the numbers look like.
The largest synthesis is a JAMA meta-analysis of 122 randomized trials with 22,803 participants. To prevent a return to any drinking, the number needed to treat was 12 for acamprosate and 20 for oral naltrexone at 50 mg daily. To prevent a return to heavy drinking, oral naltrexone's number needed to treat was 12. Head-to-head trials of acamprosate versus naltrexone found no statistically significant difference between them. Extended-release naltrexone was not associated with a reduction in returning to any drinking or to heavy drinking, but was associated with a modest reduction in heavy drinking days of about 4.6 percentage points.
Two things worth reading carefully in that paragraph. "Number needed to treat of 12" means that for every twelve people treated, roughly one avoids a return to drinking who would not have otherwise — real, modest, and far better than nothing, but not a cure. And extended-release naltrexone's honest result is weaker on abstinence than its reputation suggests.
The COMBINE study adds the head-to-head context people remember. In 1,383 recently abstinent volunteers, naltrexone at 100 mg daily plus medical management produced a higher percentage of abstinent days than placebo plus medical management (80.6 versus 75.1) and reduced the risk of a heavy drinking day. Acamprosate, at 3 grams daily, showed no significant effect on drinking in that trial, alone or in combination. One year after treatment, the between-group differences were similar but no longer statistically significant.
COMBINE is not the last word on acamprosate — European trials and the meta-analysis above support it, and the difference may reflect population, setting and how abstinence was defined. But it is the reason two clinicians can look at the same patient and reasonably propose different drugs. When the evidence cannot separate them, dosing frequency, side effects, kidney and liver function, and what the person will actually take become the deciding factors.
Who Should Not Take Which
Contraindications are not fine print here; they are how the choice gets made.
Naltrexone is out for anyone on opioid analgesics, anyone physically dependent on opioids, anyone in acute withdrawal, and anyone who failed a naloxone challenge or has opioids in their urine. It is also avoided in acute hepatitis or liver failure, and SAMHSA's expert panel advises caution when liver enzymes are more than five times the upper limit of normal unless the benefits clearly outweigh the risks.
Acamprosate is out in severe renal impairment and needs a reduced dose in moderate impairment. Because renal function declines with age, baseline and repeated kidney testing matter in people over 65. The label also advises monitoring for depression and suicidality: in controlled trials, suicidal events were infrequent but more common on acamprosate than placebo (1.4 versus 0.5 percent in studies of six months or less, and 2.4 versus 0.8 percent in year-long studies).
Disulfiram is out in severe heart disease or coronary occlusion, in psychosis, in anyone taking metronidazole or alcohol-containing preparations, and in people with sensitivity to disulfiram or thiuram derivatives used in rubber and pesticides. SAMHSA's guidance adds pregnancy and high impulsivity or suicidality. It requires caution in diabetes, hypothyroidism, epilepsy, brain damage, kidney disease and cirrhosis, and it raises the blood levels of tricyclic antidepressants and long-acting benzodiazepines.
Two more boundaries. None of these medications is FDA-approved for people under 18, so an adolescent needs a specialist rather than an off-label guess from a family physician. And in older adults, SAMHSA's guidance notes that the medications appear to be as effective and safe as in younger adults — age alone is not a reason to skip them.
What Families Can Actually Do
Ask the question in a form that gets an answer
"Do you offer medication?" invites a yes or no. Try instead: "Which of the three FDA-approved medications do you use, how do you decide between them, and who manages the prescription?" A program that uses medication will answer in detail.
Support adherence without becoming the pill police
SAMHSA lists concrete strategies — pill boxes, blister packs, a set time of day, a monitoring schedule matched to the person's history of sticking with other medication, and family involvement in monitoring where the person agrees. The agreement part is not optional. A household that turns medication into surveillance usually gets concealed nonadherence, and with disulfiram that is precisely the scenario the label warns about.
Know the small number of symptoms that mean call the prescriber
For disulfiram: fatigue, weakness, malaise, loss of appetite, nausea, vomiting, jaundice or dark urine can signal hepatitis, which the label warns may develop after many months of therapy. Liver function tests are suggested at baseline and again at 10 to 14 days.
For acamprosate: new or worsening depression, or any suicidal thinking.
For injected naltrexone: a severe or worsening reaction at the injection site, which in some cases has required surgical treatment.
Keep the counseling piece
Every trial that established these medications also included counseling, and SAMHSA recommends that anyone prescribed one receive at least brief counseling. Medication is not a replacement for the behavioral side of treatment — our guide to alcohol addiction treatment covers what the rest of a good program looks like.
One more piece of context worth knowing: some AA members hold negative views about medication, but the organization itself supports appropriate medication use. A person who wants both medication and meetings should not have to choose.
Cost, Coverage, and the Formulary Question
All three medications exist as generics, and the practical question is not list price but what your specific plan covers — whether the drug is on the formulary, whether the monthly injection is covered as a medical or pharmacy benefit, and whether prior authorization is required. Coverage varies enough by plan and state that no general statement is worth trusting.
Ask for it in writing, for the specific drug and formulation, before the first dose. Our walkthrough on verifying insurance coverage includes the exact wording to use.
If Your Family Member Says No
Medication is one option among several, and declining it is not the same as refusing help. Plenty of people recover through counseling, mutual-help groups and time, and pushing a pill onto someone who does not want it tends to cost you the relationship and gain nothing.
What does work is the approach behind CRAFT: staying engaged, setting boundaries you can actually keep, and leaving the door open for the moment the person's own motivation shifts. Our guide on supporting a loved one who refuses treatment covers how to do that without ultimatums.
Questions to Bring to the Appointment
- Which of the three medications do you recommend for this person, and why that one rather than the others?
- Have you checked liver function, kidney function, and a urine drug screen?
- Is there any opioid use — prescribed or not — in the picture, now or in the past year?
- What is the plan for the first two weeks, including who I call if something goes wrong?
- How will we know whether it is working, and when would you change course?
- Who manages refills and monitoring, and how often are follow-up visits?
- What does this cost under our plan, and is prior authorization needed?
The Bottom Line
There is no best alcohol medication in the abstract. There is a best fit for a particular person at a particular point: someone still drinking needs safe withdrawal first; someone with craving and a stable week of abstinence is a naltrexone conversation; someone with kidney concerns or a preference for a non-opioid mechanism may land on acamprosate; someone who wants an external brake and has a household willing to supervise may choose disulfiram.
What families can do is make sure the conversation happens at all. It frequently does not — a JAMA review opens by noting that alcohol use disorders remain greatly undertreated and that medications are considerably underused. Asking the question is the part that is in your hands.
If you are looking for a program that prescribes these medications, the SAMHSA National Helpline (1-800-662-4357) is free, confidential and available 24 hours a day, and SAMHSA's treatment locator lets you filter for facilities that offer medication-assisted treatment.
Sources
- SAMHSA and NIAAA — Medication for the Treatment of Alcohol Use Disorder: A Brief Guide
- NIAAA — Treatment for Alcohol Problems: Finding and Getting Help
- NIAAA — What Medications Are Available for Alcohol Use Disorder?
- FDA prescribing information — naltrexone hydrochloride tablets
- FDA prescribing information — VIVITROL (naltrexone for extended-release injectable suspension)
- FDA prescribing information — acamprosate calcium delayed-release tablets
- FDA prescribing information — disulfiram tablets
- Jonas et al., Pharmacotherapy for adults with alcohol use disorders in outpatient settings — JAMA meta-analysis
- Anton et al., Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) — JAMA
You might also read


